Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 22,562 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $28.50, for a total transaction of $643,017.00. Following the completion of the sale, the chief executive officer owned 496,835 shares of the company’s stock, valued at $14,159,797.50. This trade represents a 4.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Monday, May 11th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $29.12, for a total transaction of $657,005.44.
• On Friday, April 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $26.72, for a total transaction of $602,856.64.
• On Wednesday, March 18th, John C.M. Farquhar sold 9,725 shares of Heartflow stock. The shares were sold at an average price of $25.00, for a total transaction of $243,125.00.

Heartflow Trading Up 8.4%

Shares of NASDAQ:HTFL opened at $33.24 on Friday. The firm has a 50 day moving average of $29.30 and a 200-day moving average of $28.34. The stock has a market capitalization of $2.87 billion and a PE ratio of -10.69. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.08. The company had revenue of $52.59 million for the quarter. The business’s revenue for the quarter was up 41.3% compared to the same quarter last year. On average, research analysts predict that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. TrueMark Investments LLC lifted its position in shares of Heartflow by 1.4% during the 1st quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock valued at $654,000 after acquiring an additional 379 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Heartflow during the fourth quarter worth $27,000. Strs Ohio raised its holdings in Heartflow by 35.3% during the first quarter. Strs Ohio now owns 4,600 shares of the company’s stock worth $112,000 after buying an additional 1,200 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Heartflow during the fourth quarter worth $45,000. Finally, Legal & General Group Plc acquired a new position in Heartflow during the third quarter worth $59,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating on shares of Heartflow in a research note on Thursday. William Blair assumed coverage on shares of Heartflow in a research note on Monday, May 4th. They set an “outperform” rating for the company. Wells Fargo & Company raised their price target on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Canaccord Genuity Group reduced their price objective on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, March 19th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.00.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.